3 New Strong Buy Ratings from Top-Rated Analysts: 10/03/2025
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Nextracker (NXT) dominates its industry — and something big is afoot
- Guardian Pharmacy Services (GRDN) is a low-priced stock with strong tailwinds
- Why BioMarin Pharmaceutical (BMRN) is the jewel of our Buy the Dip portfolio
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
_________________
Goldman Sachs: "More Than 1,600 New Millionaires Quietly Being Anointed Due to Breakthrough Technology" And that's only the beginning... Jeff Bezos, Mark Zuckerberg, Bill Gates, Jensen Huang, and Elon Musk are all quietly investing millions in a secret revolutionary technology. You've never heard anything like this before... Click here to watch this special investigative documentary.*
*Our sponsors help keep this content free
_________________
1. Nextracker (NASDAQ: NXT)
Nextracker has a 23% share of the global solar tracker market. The company’s products are essential for keeping large-scale renewable energy projects efficient. NXT has surged by more than 80% since the start of 2025 — the company recently delivered an earnings beat (its 9th consecutive one), and we also have a hefty $4.5 billion (yes, with a b) backlog. Wanna know the best part? The stock is still trading at roughly half the wider market’s average P/E ratio.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $72.30 — get current quote >
Max 1-year forecast: $80.00
Why we’re watching:
- Nextracker shares enjoy broad support from Wall Street analysts. The stock currently has 10 Strong Buy ratings, 1 Buy rating, and 2 Hold ratings. See the ratings
- JP Morgan researcher Mark Strouse (a top 6% rated analyst) recently maintained a Strong Buy rating on the stock and hiked his price target from $69 to $77.
- In a technical note, Strouse told readers they adjusted their price target after updating the target date in their Clean Energy sector model from 2025/12 to 2026/12.
- Our quant rating system, Zen Ratings, evaluates more than 4,600 stocks on the basis of 115 proprietary factors every day. Stocks that rank in the top 5% have a Zen Rating of A, which has historically corresponded to an average annualized return of 32.52%. At present, NXT ranks in the top 5% of equities.
- Each Zen Rating is a composite score made up of 7 Component Grade ratings. For instance, Nextracker ranks in the 85th percentile in terms of Value, on account of a very attractive 19.4x price-to-earnings (P/E) ratio.
- NXT also ranks in the top 9% of stocks when it comes to Momentum, and the top 7% with regard to Financials. (See all 7 Zen Component Grades here >)
2. Guardian Pharmacy Services (NYSE: GRDN)
One of the largest long-term care pharmacy operators in the United States, Guardian Pharmacy Services provides specialized medication management to senior living communities, skilled nursing facilities, and individuals with complex health needs. With an aging population driving higher demand for long-term care and specialized pharmacy support, Guardian is positioned as a key player in a growing healthcare niche
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $26.01 — get current quote >
Max 1-year forecast: $30.00
Why we’re watching:
- GRDN is an under-the-radar pick — only 1 Wall Street analyst tracks the stock, and he issues a Strong Buy rating. See the rating
- The researcher in question is David S Macdonald of Truist Securities (a top 12% rated analyst), who recently maintained a Strong Buy rating on the stock and hiked his price target from $28 to $30.
- Macdonald reported that they met with Guardian Pharmacy Services' management and that their takeaways catalyzed their price target hike and optimistic view of the name.
- The analyst argued that Guardian Pharmacy Services holds an advantageous position in a market characterized by robust core demand, overall favorable trends, and continuous opportunities for growth..
- Macdonald detailed that the company's fundamental trends remain robust, and its recently acquired assets offer promising opportunities for earnings growth.
- GRDN is currently the 4th highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A.
- Guardian Pharmacy Services shares rank in the 96th percentile of the equities that we track, giving them a Zen Rating of A.
- In terms of its Financials Component Grade rating, GRDN currently ranks in the top 8% of stocks.
- When it comes to Sentiment, Guardian Pharmacy Services ranks in the top 7% of equities.
- Last, but certainly not least, we have Safety — a category in which GRDN ranks in the top 4%. (See all 7 Zen Component Grades here >)
A note from our sponsors...
New Way of Trading Has Gone Viral Imagine foreseeing a 30% stock jump - to the day - weeks before it happens. We've developed a way to predict the biggest stock jumps this spring, to the day, with 83% backtested accuracy. In 2024 alone, it would've pointed to gains of 250% in 38 days on (TTWO)... 101% in 10 days on (WSM)... 353% in 48 days on (AON) and more in studies. Click here for instant access to our #1 new stock pick, free of charge.3. BioMarin Pharmaceutical (NASDAQ: BMRN)
BioMarin is a tried-and-tested biopharma play that has been in business for 27 years. The company maintains a robust pipeline of treatments aimed at rare diseases. Despite an impressive performance in the company’s last earnings report, BMRN shares are down by 8.12% on the monthly chart. However, the fundamentals are there — so now might be an opportune time to buy the dip.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $54.28 — get current quote >
Max 1-year forecast: $114.00
Why we’re watching:
- Analyst coverage of BMRN skews strongly to the bullish side. The stock currently has 5 Strong Buy ratings and 2 Hold ratings. See the ratings
- Guggenheim researcher Debjit Chattopadhyay (a top 10% rated analyst) maintained a Strong Buy rating on the stock last month, and hiked his price target from $101 to $106.
- Meanwhile, Eliana Merle of UBS (a top 18% rated analyst) also doubled down on a Strong Buy rating, and increased her price target from $113 to a Street-high $114.
- BioMarin Pharmaceutical shares have seen an 8.12% dip in the past month, but retain stellar fundamentals. This has secured a spot for the stock in our exclusive Zen Strategies Buy the Dip portfolio, which has an all-time annual return of 35.29%.
- BMRN has a Zen Rating of A, and currently ranks in the top 2% of the more than 4,600 stocks that we track.
- BioMarin enjoys the benefits of a strong balance sheet — the stock ranks in the 92nd percentile in terms of Financials.
- Our Artificial Intelligence Component Grade rating uses a neural network trained on two decades of market data to identify likely outperformers. In this category, BMRN ranks in the top 5% of stocks.
- Sentiment and Value are also sparkling — in both of these areas, the stock ranks in the top 3% of equities. (See all 7 Zen Component Grades here >)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.